Robert W. Baird Lowers Elevance Health (NYSE:ELV) Price Target to $317.00

Elevance Health (NYSE:ELV) had its target price decreased by equities research analysts at Robert W. Baird from $340.00 to $317.00 in a research note issued on Wednesday,MarketScreener reports. The brokerage currently has a “neutral” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 0.60% from the stock’s current price.

ELV has been the topic of a number of other reports. Mizuho decreased their price objective on Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Wolfe Research set a $425.00 target price on Elevance Health and gave the stock an “outperform” rating in a report on Thursday, January 8th. Jefferies Financial Group cut their target price on Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Sanford C. Bernstein decreased their price target on Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Finally, Truist Financial lowered their price target on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research report on Monday. Twelve research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $383.57.

Elevance Health Price Performance

ELV stock opened at $315.10 on Wednesday. Elevance Health has a 52 week low of $273.71 and a 52 week high of $437.99. The firm has a market capitalization of $69.21 billion, a P/E ratio of 12.54, a price-to-earnings-growth ratio of 1.71 and a beta of 0.49. The company has a fifty day simple moving average of $309.30 and a two-hundred day simple moving average of $331.83. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period in the previous year, the firm posted $3.84 EPS. The business’s quarterly revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts anticipate that Elevance Health will post 33.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elevance Health

A number of institutional investors and hedge funds have recently modified their holdings of ELV. Vanguard Group Inc. lifted its position in shares of Elevance Health by 0.6% during the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after purchasing an additional 141,747 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Elevance Health by 25.2% in the fourth quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after purchasing an additional 1,668,679 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Elevance Health by 27.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock worth $2,610,261,000 after purchasing an additional 1,607,274 shares during the last quarter. Artisan Partners Limited Partnership increased its stake in Elevance Health by 10.0% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,032,751 shares of the company’s stock worth $1,764,231,000 after buying an additional 455,946 shares during the period. Finally, First Eagle Investment Management LLC increased its stake in Elevance Health by 0.6% in the 4th quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock worth $1,410,219,000 after buying an additional 24,271 shares during the period. 89.24% of the stock is owned by institutional investors.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.